The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats

[1]  Sujata Sharma,et al.  From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9. , 2019, Cell chemical biology.

[2]  M. Jandrot-Perrus,et al.  Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development. , 2018, New biotechnology.

[3]  A. Prat,et al.  A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice , 2018, Biological chemistry.

[4]  M. Davidson,et al.  PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety. , 2018, Reviews in cardiovascular medicine.

[5]  A. Peterson,et al.  Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists , 2017, Nature Structural &Molecular Biology.

[6]  Ben D. Chen,et al.  Increased half-life and enhanced potency of Fc-modified human PCSK9 monoclonal antibodies in primates , 2017, PloS one.

[7]  R. Zeldin,et al.  Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura , 2017, Journal of thrombosis and haemostasis : JTH.

[8]  A. Prat,et al.  Proprotein convertase subtilisin/Kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of low density lipoprotein receptor degradation. , 2016, Journal of Biological Chemistry.

[9]  R. Arbel,et al.  PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them? , 2016, International Journal of Cardiology.

[10]  Jian Wang,et al.  Comparative Analysis of Immune Repertoires between Bactrian Camel's Conventional and Heavy-Chain Antibodies , 2016, PloS one.

[11]  P. Thompson,et al.  Statins and Their Effect on PCSK9—Impact and Clinical Relevance , 2016, Current Atherosclerosis Reports.

[12]  A. Prat,et al.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation* , 2016, The Journal of Biological Chemistry.

[13]  R. Kontermann.  Half-life extended biotherapeutics , 2016, Expert opinion on biological therapy.

[14]  F. Perez,et al.  Bacterial cytoplasm as an effective cell compartment for producing functional VHH-based affinity reagents and Camelidae IgG-like recombinant antibodies , 2014, Microbial Cell Factories.

[15]  P. Madsen,et al.  Expression of single-chain variable fragments fused with the Fc-region of rabbit IgG in Leishmania tarentolae , 2014, Microbial Cell Factories.

[16]  A. Knappik,et al.  Off-rate screening for selection of high-affinity anti-drug antibodies. , 2013, Analytical biochemistry.

[17]  J. Queiroz,et al.  Pichia pastoris: a recombinant microfactory for antibodies and human membrane proteins. , 2013, Journal of microbiology and biotechnology.

[18]  H. Bundgaard,et al.  Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. , 2013, Journal of the American College of Cardiology.

[19]  A. Peterson,et al.  Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels , 2012, The Journal of Biological Chemistry.

[20]  A. Saremi,et al.  Progression of Vascular Calcification Is Increased With Statin Use in the Veterans Affairs Diabetes Trial (VADT) , 2012, Diabetes Care.

[21]  M. Muda,et al.  Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. , 2011, Protein engineering, design & selection : PEDS.

[22]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[23]  Etienne Weiss,et al.  Therapeutic antibodies: successes, limitations and hopes for the future , 2009, British journal of pharmacology.

[24]  J. Mayne,et al.  Plasma PCSK9 levels are significantly modified by statins and fibrates in humans , 2008 .

[25]  R. Hammer,et al.  Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. , 2006, The Journal of clinical investigation.

[26]  E. Remaut,et al.  Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. , 2006, Arthritis and rheumatism.

[27]  J. Tanha,et al.  Prokaryotic expression of antibodies , 2005, Cancer and Metastasis Reviews.

[28]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[29]  A. Prat,et al.  The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. W. Bos,et al.  Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. , 2000, Journal of biotechnology.

[31]  L. Wyns,et al.  Selection and identification of single domain antibody fragments from camel heavy‐chain antibodies , 1997, FEBS letters.

[32]  R. Hammer,et al.  Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. , 1996, The Journal of clinical investigation.

[33]  R. Glockshuber,et al.  A comparison of strategies to stabilize immunoglobulin Fv-fragments. , 1990, Biochemistry.

[34]  R. Hammer,et al.  Overexpression of low density lipoprotein (LDL) receptor eliminates LDL from plasma in transgenic mice. , 1988, Science.

[35]  C. Napoli,et al.  Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias. , 2019, Current pharmaceutical design.

[36]  S. Muyldermans,et al.  Generation of single domain antibody fragments derived from camelids and generation of manifold constructs. , 2012, Methods in molecular biology.